Schering-Plough invest $60M in R&D units
US pharmaceutical major Schering-Plough has revealed supporting its global R&D activities. The company is investing a total of $60.0 million across three of its worldwide locations in Scotland, the USA and the Netherlands. Half of the investment is to be spent at its Newhouse facility in Scotland.
Making the announcement at the Scottish Enterprise Life Sciences annual dinner, John Swinney, Cabinet Secretary for Finance and Sustainable Growth, said: "Schering-Plough's decision to make this substantial investment in its Newhouse facility is a welcome boost for Scotland's life science industry."
Ismail Kola, senior vice president, discovery research, S-P Research Institute, and chief scientific officer, added: "with the Organon Biosciences acquisition in November 2007, Schering-Plough is creating a stronger combined company with increased R&D capabilities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze